Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease - PubMed
3 months ago
- #Alzheimer's disease
- #BIIB080
- #clinical trial
- Exploratory analyses of BIIB080, a MAPT-targeting antisense oligonucleotide, in mild Alzheimer's disease.
- Phase 1b trial included placebo-controlled, multiple-ascending dose (MAD) and open-label, long-term extension (LTE) phases.
- Participants received varying doses of BIIB080 (10 mg, 30 mg, 60 mg every 4 weeks or 115 mg every 12 weeks).
- BIIB080 was generally well tolerated with a trend of slowed cognitive, functional, and global decline in high-dose groups.
- Reductions in brain neurofibrillary tangles were observed via tau positron emission tomography.
- Trial registration: ClinicalTrials.gov identifier: NCT03186989.